Angiogenesis , Metastasis , and the Cellular Microenvironment Atypical Protein Kinase C i ( PKC i ) Promotes Metastasis of Esophageal Squamous Cell Carcinoma by Enhancing Resistance to Anoikis via PKC i-SKP 2-AKT Pathway

Shu-Guang Liu,Bo-Shi Wang,Yan-Yi Jiang,Tong-Tong Zhang,Zhi-Zhou Shi,Yang Yang,Yi-Ling Yang,Xiao-Chun Wang,De-Chen Lin,Hai Yang,Yan Cai,Qi-Min Zhan,Ming-Rong Wang

2011-01-01

Abstract:Protein kinase Ci (PKCi) is an atypical PKC isoform and participates in multiple aspects of the transformed phenotype in human cancer cells. We previously reported that frequent amplification and overexpression of PKCi were correlated with lymph node metastasis in primary esophageal squamous cell carcinomas (ESCC). In the present study, short interfering RNA–mediated silencing of PKCi revealed that this enzyme was required for cell migration, invasion, and resistance to anoikis. In vivo experiments showed that PKCi suppression decreased tumor growth in esophageal cancer xenografts and lung metastases in nude mice. At the molecular level, knockdown of PKCi in suspended ESCC cells caused a decrease in S-phase kinase-associated protein 2 (SKP2) that had been reported to promote resistance to anoikis via the PI3K/AKT pathway. AKT phosphorylation was abolished after PKCi suppression, but AKT activation could be refreshed by PKCi upregulation, suggesting that PKCi enhanced cell resistance to anoikis via the PKCi-SKP2-PI3K/AKT pathway. Addition of the proteasome inhibitor MG132 prevented the decrease of SKP2 in PKCi silenced cells, and polyubiquitin-SKP2 was elevated after PKCi depletion, showing that PKCimight regulate the expression of SKP2 through the ubiquitin-proteasome pathway in suspended cells. Furthermore, overexpression of SKP2 in PKCi-downregulated cells restored cell resistance to anoikis. Most importantly, PKCi expression significantly correlated with SKP2 in 133 ESCC tissues (P1⁄4 0.031). Taken together, our data show that PKCi promotes tumorigenicity and metastasis of human esophageal cancer and that SKP2 is a candidate downstream effector of PKCi signaling in ESCC. Mol Cancer Res; 9(4); 390–402.